Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
How Well Do Docs Manage Potential Conflicts Between Hep C and HIV Meds?

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Published
10 April 2018
From
Poz
TAF only superior to TDF when used with a boosting agent

The benefits of tenofovir alafenamide (TAF) over tenofovir disoproxil fumarate (TDF) may have been overstated, according to the results of a meta-analysis published in the

Published
10 April 2018
By
Michael Carter
Twice-daily dolutegravir is safe and effective when used alongside TB treatment

Twice-daily dosing of dolutegravir when combined with the tuberculosis (TB) drug rifampicin is safe and effective and will allow dolutegravir to be used alongside TB treatment as

Published
07 March 2018
By
Keith Alcorn
Dolutegravir and Rifapentine study stopped due to serious toxicities

A study examining pharmacokinetic interactions between the first-line HIV drug dolutegravir and a once-weekly tuberculosis regimen was terminated early after NIH researchers found that the combined use of the treatments led to “unexpected and serious toxicities” in healthy participants.

Published
01 March 2018
From
Medical Brief
Taking multiple Rx drugs raises risks for aging adults with and without HIV

Taking five or more prescription medications increases the risk of hospitalization and death in older adults infected with HIV and comparable adults without HIV. The findings of this Yale-led study highlight the potential risks of prescribing additional drugs to patients with multiple medical conditions.

Published
01 February 2018
From
Yale News
New 'mini-pillbox' device could deliver three HIV drugs in a single once-weekly dose

A new oral device that is taken once a week in a capsule could deliver two or three antiretroviral drugs and significantly reduce the risk

Published
09 January 2018
By
Keith Alcorn
Experts concur that event-related oral PrEP probably won’t work for women

Two presentations at the recent International AIDS Society Conference on HIV Science (IAS 2017) in Paris told delegates that both trial results and analysis of drug

Published
01 September 2017
By
Gus Cairns
Trans women wary of antiretroviral drug and hormone interactions

Transgender women living with HIV may be hesitant to use antiretroviral therapy (ART) or not take it as prescribed because of concerns about drug interactions with feminising hormones,

Published
23 August 2017
By
Liz Highleyman
Drug interaction concerns may negatively affect HIV treatment adherence among transgender women

Participants in NIH-supported study apprehensive about combining HIV medications and hormones.

Published
25 July 2017
From
NIAID
Taking Birth Control With HIV Treatment or PrEP Is Largely OK

Women taking various forms of hormonal contraceptives can likely combine them safely with antiretrovirals (ARVs), whether as HIV treatment or in the form of Truvada (tenofovir disoproxil fumarate/emtricitabine) as pre-exposure prophylaxis (PrEP) against the virus. The one ARV that may be problematic to combine with such forms of birth control is Sustiva (efavirenz), which is included in Atripla (efavirenz/tenofovir disoproxil fumarate/emtricitabine).

Published
30 May 2017
From
Poz
← First12345...22Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.